Company intelligence / Profile preview

Kaysoft

Seattle or unspecified city in New Jersey, Washington or New Jersey, United Stateshostadvice.com ↗

Ownership: Private
Development stage: Other

Overview

Kayothera is developing first-in-class oral small molecules targeting previously undruggable nuclear receptor pathways and the HSF1 pathway. Its lead candidate, KAYO-1609, targets HSF1 for cancer therapy and is expected to enter clinical trials soon. The company has raised significant venture funding and expanded its scientific advisory board with leading experts in translational medicine. No clinical results are available yet as programs are preclinical.[1][2][3]

Therapeutic areas: OncologyEndocrinology
Modalities: Small molecule
Industry: Biotech

Partnerships

None publicly disclosed as of June 2025.

Beyond the preview

Go deeper on Kaysoft.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Kaysoft.

Explore the full profile